Consensus Aligos Therapeutics, Inc.

Stocks

ALGS

US01626L2043

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-07 EDT			5-day change	1st Jan Change
5.320 ^USD	-1.12%		-5.51%	-42.92%

08-12	Aligos Therapeutics Initiates Dosing in Phase 1 Study of Alg-170675 for Chronic Hepatitis B Virus Infection	CI
08-06	Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Aligos Therapeutics, Inc.

Evolution of the Target Price: Aligos Therapeutics, Inc.

Changes in Analyst Recommendations: Aligos Therapeutics, Inc.

669e25fb1a1a.a2zU1IfJA5TPbrcDlzGev1ZqG5Ah5k3ZRw7USos4SQ0.Mxa9n9enWdfiLd5s1Ujr_RlbWfx4pTzuLz6fBdEOB39SJLmetoI1_IEL4g~43ea66669d8d9430e52c1bf328f6dc93

Analysts' recommendations: Aligos Therapeutics, Inc.

05-28	Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target	MT
01-07	UBS Initiates Aligos Therapeutics at Buy With $20 Price Target	MT
24-08-19	HC Wainwright Initiates Aligos Therapeutics at Buy With $75 Price Target	MT
23-01-17	Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating	MT
23-01-06	Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2	MT
23-01-06	Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50	MT
22-11-03	SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating	MT
22-08-08	Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11	MT
22-05-05	SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7	MT
22-03-23	Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating	MT
22-03-23	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating	MT
22-03-23	Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15	MT
22-03-11	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating	MT
22-02-16	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating	MT
22-01-07	Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20	MT
22-01-07	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating	MT
22-01-07	JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30	MT
21-09-09	Aligos Therapeutics : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target	MT
21-05-17	Aligos Therapeutics : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target	MT
21-03-24	Aligos Therapeutics : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating	MT
20-12-21	Aligos Therapeutics : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating	MT
20-11-10	Aligos Therapeutics : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target	MT
20-11-10	Aligos Therapeutics : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target	MT
20-11-10	Aligos Therapeutics : JPMorgan Starts Aligos Therapeutics at Overweight With $33 Price Target	MT
20-11-10	Aligos Therapeutics : Jefferies & Co Initiates Coverage on Aligos Therapeutics With Buy Rating, $26 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALIGOS THERAPEUTICS, INC.					+884.49%
	WUXI APPTEC CO., LTD.					+13.99%
	ARGENX SE					+24.63%
	LONZA GROUP AG					+19.23%
	REVOLUTION MEDICINES, INC.					+28.86%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+19.55%
	CELLTRION, INC.					+45.91%
	BIONTECH SE					+22.24%
	INSMED INCORPORATED					+94.36%
	Average					+116.65%
	Weighted average by Cap.					+26.23%